These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30309623)

  • 21. Targeted Inhibitors: Novel Strategies for Response Optimization.
    Kurzrock R
    Semin Oncol; 2015 Dec; 42(6):773-4. PubMed ID: 26615124
    [No Abstract]   [Full Text] [Related]  

  • 22. [Determination of blood levels for oral anticancer drugs].
    van Erp NP; van der Graaf WT
    Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
    Levêque D; Becker G
    Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mecanisms of pharmacokinetic interactions involving oral anticancer agents].
    Levêque D; Duval C; Poulat C; Palas B; El Aatmani A; Dory A; Becker G; Gourieux B
    Bull Cancer; 2015 Jan; 102(1):65-72. PubMed ID: 25609481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determining the optimal dose in the development of anticancer agents.
    Mathijssen RH; Sparreboom A; Verweij J
    Nat Rev Clin Oncol; 2014 May; 11(5):272-81. PubMed ID: 24663127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions with solid tumour-targeted therapies.
    Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.
    Verbrugghe M; Duprez V; Beeckman D; Grypdonck M; Quaghebeur M; Verschueren C; Verhaeghe S; Van Hecke A
    Cancer Nurs; 2016; 39(2):153-62. PubMed ID: 25815430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead.
    Evans WE; Pui CH; Yang JJ
    Clin Pharmacol Ther; 2020 Jan; 107(1):176-180. PubMed ID: 31563145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
    Keller KL; Franquiz MJ; Duffy AP; Trovato JA
    J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
    Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
    JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use.
    Gougis P; Palmieri LJ; Funck-Brentano C; Paci A; Flippot R; Mir O; Coriat R
    Crit Rev Oncol Hematol; 2019 Sep; 141():112-124. PubMed ID: 31276964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
    Wang R; Zhong C; Zhang C; Hua M; Ma D
    Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
    Calvo E; Walko C; Dees EC; Valenzuela B
    Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
    Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
    J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.
    Liu S; Nikanjam M; Kurzrock R
    Oncotarget; 2016 Mar; 7(10):11310-20. PubMed ID: 26824502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug interactions in oncology.
    Beijnen JH; Schellens JH
    Lancet Oncol; 2004 Aug; 5(8):489-96. PubMed ID: 15288238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.